Browse our clinical trial protocol synopses
- Cutaneous leishmaniasis
DNDi-LXE408-03-CL / CLXE408C12201R
Efficacy, safety, and pharmacokinetics of two LXE408 regimens for localized cutaneous leishmaniasis in the region of the Americas
- Latin America
- Filaria: river blindness
DNDI-TYL-01
Tylamac phase-II trial for treatment of onchocerciasis
- Democratic Republic of Congo, Africa
- Cutaneous leishmaniasis
DNDi-MILT-08-CL
Efficacy and safety of thermotherapy plus miltefosine for cutaneous leishmaniasis in South America
- Colombia, Latin America, Peru
- Hepatitis C
DNDi-RDV-04-HCV
Bioequivalence study of test and reference ravidasvir for chronic HCV (in healthy fed participants)
- Asia, Malaysia
- Sleeping sickness
DNDi-OXA-07-HAT
A drug-drug interaction study of acoziborole for T. b. gambiense sleeping sickness (in healthy male participants)
- Asia, Malaysia
- Sleeping sickness
DNDi-OXA-05-HAT
Pharmacokinetics, efficacy, safety, and tolerability of acoziborole in children with T. b. gambiense sleeping sickness
- Africa, Democratic Republic of Congo
- Sleeping sickness
DNDi-OXA-04-HAT
Safety and tolerability of acoziborole for seropositive non-parisitologically confirmed T. b. gambiense sleeping sickness
- Africa, Democratic Republic of Congo, Guinea
- Visceral leishmaniasis
DNDi-MILT/PM-01-VL
Efficacy and safety of paromomycin plus miltefosine or sodium stibogluconate for visceral leishmaniasis in Africa
- Africa, Ethiopia, Kenya, Uganda, Sudan
- Visceral leishmaniasis
DNDi-LXE408-02-VL / CLXE408A12202R
Efficacy, safety, and pharmacokinetics of LXE408 for primary visceral leishmaniasis in Ethiopia
- Africa, Ethiopia
- Visceral leishmaniasis
DNDi-LXE408-01-VL / CLXE408A12201R
Efficacy and safety of two LXE408 regimens for primary visceral leishmaniasis in India
- Asia, India
- Hepatitis C
DNDi-RDV-02-HCV
Bioequivalence study of test and reference ravidasvir tablets for chronic HCV (in healthy fed participants)
- Asia, Malaysia
- Chagas disease
DNDi-FEX-12-CH
Efficacy and safety of fexinidazole for undetermined chronic Chagas disease
- Europe, Spain
- Filaria: river blindness
DNDI-EMO-03
Tolerability, safety, and bioavailability study of immediate release emodepside for river blindness (in healthy participants)
- Europe, United Kingdom
- Filaria: river blindness
DNDI-EMO-02
Safety, tolerability, and pharmacokinetics of emodepside for river blindness (in healthy participants)
- Europe, United Kingdom
- Cutaneous leishmaniasis
DNDi-CpG-001
Safety, tolerability, pharmacokinetics, and pharmacodynamics of CpG ODN D35 for cutaneous leishmaniasis (in healthy participants)
- Europe, United Kingdom
- Cryptococcal meningitis
DNDi-5FC-02-CM
Bioavailability study of immediate release flucytosine for cryptococcal meningitis (in healthy fed participants)
- Africa, South Africa
- Cryptococcal meningitis
DNDi-5FC-01-CM
Bioavailability study of immediate release flucytosine for cryptococcal meningitis (in healthy fasting participants)
- Africa, South Africa
- Cutaneous leishmaniasis, Visceral leishmaniasis
DNDi-6148-01
Safety, tolerability, and pharmacokinetics of single dose DNDI-6148 for visceral leishmaniasis (in healthy participants)
- Europe, France
- Cutaneous leishmaniasis, Visceral leishmaniasis
DNDi‐0690‐02
Safety, tolerability, and pharmacokinetics of multiple dose DNDI-0690 for visceral leishmaniasis (in healthy participants)
- Europe, United Kingdom
- Visceral leishmaniasis
DNDi-0690-01
Safety, tolerability, and pharmacokinetics of single dose DNDI-0690 for visceral and cutaneous leishmaniasis (in healthy participants)
- Europe, United Kingdom
- Pandemic Preparedness
ANTICOV
Platform trial of efficacy and safety of several therapies for mild / moderate COVID-19
- Africa, Ghana, Guinea, Kenya, Sudan, Uganda, Mali, Brazil, Burkina Faso, Cameroon, Côte d’Ivoire, Democratic Republic of Congo, Ethiopia, Latin America, Tanzania, Mozambique
- Visceral leishmaniasis
DNDi-MILT COMB-02-PKDL
Efficacy and safety of miltefosine plus either liposomal amphotericin B or paromomycin for PKDL in Sudan
- Africa, Sudan
- Visceral leishmaniasis
DNDi-MILT COMB-01-PKDL
Efficacy and safety of liposomal amphotericin B alone and in combination with miltefosine for PKDL in Asia
- Asia, Bangladesh, India
- Mycetoma
DNDi-FOSR-04-MYC
Comparative efficacy of two fosravuconazole doses with itraconazole for eumycetoma, in combination with surgery
- Africa, Sudan
- Chagas disease
DNDi-CH-E1224-003
Efficacy and safety of shorter benznidazole regimens and E1224 for chronic Chagas disease
- Bolivia, Latin America
- Hepatitis C
DNDi-SOF/RDV-01-HCV
Efficacy, safety, tolerance, and pharmacokinetics of sofosbuvir plus ravidasvir for chronic HCV
- Asia, Thailand, Malaysia
- Sleeping sickness
DNDi-OXA-03-HAT
Absorption, metabolism, and excretion of acoziborole for sleeping sickness (in healthy participants)
- Europe, United Kingdom
- Sleeping sickness
DNDi-OXA-02-HAT
Efficacy and safety of acoziborole for T.b. gambiense sleeping sickness
- Africa, Democratic Republic of Congo, Guinea
- Sleeping sickness
DNDi-HAT-FEX-006
Efficacy and safety of fexinidazole for T. b. gambiense sleeping sickness in children
- Africa, Democratic Republic of Congo
- Sleeping sickness
DNDi-HAT-FEX-005
Efficacy and safety of fexinidazole for stage 1 & early stage 2 T. b. gambiense sleeping sickness
- Africa, Democratic Republic of Congo
- Sleeping sickness
DNDi-FEX-09-HAT
Efficacy, safety and adherence with fexinidazole for any stage of T.b. gambiense sleeping sickness
- Democratic Republic of Congo, Guinea, Africa
- Sleeping sickness
DNDi-FEX-07-HAT
Efficacy and safety of fexinidazole for T.b. rhodesiense sleeping sickness
- Africa, Uganda, Malawi
- Sleeping sickness
DNDi-FEX-004
Efficacy and safety of fexinidazole for late-stage T.b. gambiense sleeping sickness
- Africa
To request access to data from any of DNDi’s clinical trials, please visit the website of our data-sharing partner, Vivli, to make a data request.
Project portfolio
We are working on more than 40 research and treatment access projects, including more than 20 focused on identifying or developing new chemical entities.
Scientific articles
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
